Study: Population size: 766, human Lead Researcher: Benozzi, Argentina Presented: Sept 2025 Study design: retrospective, eye drops, active ingredients: * pilocarpine, a drug that constricts the pupils and contracts the ciliary muscle, which is a muscle controlling the eye's accommodation for seeing objects at varying distances, and * diclofenac, a non-steroidal anti-inflammatory drug (NSAID) that reduces inflammation and the discomfort that pilocarpine often causes. Results: found that the majority could read an extra two, three or more lines on a standard eye chart, reducing dependence on reading glasses. Commentary/caution: Prof Burkhard Dick (ESCRS President-Elect, chair, ophthalmology dept at Uni Eye Hosp in Germany), commented: some patients are not candidates for surgery to repair age-related near vision loss. Benozzi’s study suggests that eye drops (containing pilocarpine and diclofenac) may improve near vision, but the study design means the results may not apply to everyone. Long-term pilocarpine use can sometimes cause side effects such as reduced night vision, dimmer vision in low light, eye strain, irritation and, in rare cases, retinal detachment, while prolonged topical NSAID use may pose corneal risks. More studies are needed to confirm safety and effectiveness before this treatment can be widely recommended.